Bristol-Myers Squibb and Pfizer reach a new milestone for their anticoagulant.
Is the relative stability provided by Johnson & Johnson's diversified business model a major advantage when compared to Pfizer and Bristol-Myers Squibb?
Shares in Bristol-Myers Squibb performed relatively positively last week. Can they keep it going?
Merck, Bristol-Myers and Roche head the race to pioneer PD-1 therapies.
The year 2013 was a great one for Bristol-Myers Squibb (NYSE: BMY); 2014 could also be a strong year due to a potential catalyst.
Sangamo Biosciences shot up 20% today, but this may still be one to watch at a distance.
Recently published long-term survival data for nivolumab is so promising that short term concerns seem trivial.
Merck may be on the verge of making a very big move.
Bristol-Myers and AstraZeneca offer nice dividend yields, but patent expiration may mean dividend investors are taking on risk.
Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, and Merck top the charts.